Exploiting hypoxia in solid malignancies to restrict expression of chimeric antigen receptors (CARs) on engineered T?cells to the tumor microenvironment overcomes the risk of on-target off-tumor toxicity and minimizes tonic signaling, which promotes CAR T?cell exhaustion. This protocol summarizes the synthetic biology underlying the development of a stringent oxygen-sensitive CAR for and preclinical characterization. For complete details on the use and execution of this protocol, please refer to Kosti et?al. (2021).
Exploiting hypoxia in solid malignancies to restrict expression of chimeric antigen receptors (CARs) on engineered T?cells to the tumor microenvironment overcomes the risk of on-target off-tumor toxicity and minimizes tonic signaling, which promotes CAR T?cell exhaustion. This protocol summarizes the synthetic biology underlying the development of a stringent oxygen-sensitive CAR for and preclinical characterization. For complete details on the use and execution of this protocol, please refer to Kosti et?al. (2021).
